Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12621000775819
Ethics application status
Approved
Date submitted
26/05/2021
Date registered
21/06/2021
Date last updated
14/07/2024
Date data sharing statement initially provided
21/06/2021
Type of registration
Prospectively registered

Titles & IDs
Public title
Comparative assessment of the absorption of a generic formulation of Dimethyl (2E)-but-2-enedioate capsule against the innovator Dimethyl (2E)-but-2-enedioate capsule conducted under fasting condition in healthy male and female volunteers.
Scientific title
A single dose, randomized, blinded, two-treatment, three period, three-sequence, partial replicate, reference scaled crossover study comparing a test formulation of Dimethyl (2E)-but-2-enedioate capsule in a 3 way crossover comparison against the innovator Dimethyl (2E)-but-2-enedioate capsule conducted under fasting conditions in healthy male and female volunteers.
Secondary ID [1] 304266 0
None
Universal Trial Number (UTN)
U1111-1265-3300
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Dimethyl (2E)-but-2-enedioate is indicated in patients with relapsing multiple sclerosis to reduce the frequency of relapses and to delay the progression of disability. 321990 0
Condition category
Condition code
Neurological 319709 319709 0 0
Multiple sclerosis

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Single dose, 3 period, partial replicate, reference scaled, crossover study design whereby each participant receives the test formulation of 240 mg Dimethyl (2E)-but-2-enedioate capsule on one occasion and the innovator formulation of 240 mg Dimethyl (2E)-but-2-enedioate capsule on two occasions with each dose separated by a one week washout period. The intervention for this trial is the test capsule formulation.

No water is allowed for 1 hour prior to dosing until 1 hour after dosing (except for water consumed with the dose).
Participants are required not to eat for 10 hours before receiving each dose and to fast for approximately 4 hours after receiving each dose.

Standard meals will be consumed at the Clinical Site with no additional food intake allowed. Alcohol breath testing will be performed upon each participant reporting to the Clinical Site 10 hours prior to dosing.

Pre and post study laboratory tests will be completed to assess the health of participants along with HIV, Hepatitis and drugs of abuse testing.

Each dose ( 1 x 240 mg) will be taken orally with 240 ml of water at ambient temperature. Medication must be swallowed whole and a mouth check will be conducted to ensure the medication has been taken as directed.
Intervention code [1] 320605 0
Treatment: Drugs
Comparator / control treatment
Single dose, 3 period, partial replicate, reference scaled, crossover study whereby each participant receives the test formulation (1 x 240 mg) on one occasion and the innovator formulation of Dimethyl (2E)-but-2-enedioate (1 x 240 mg) on two occasions with each dose separated by a one week washout period. The comparator/control for this trial is the innovator capsule formulation.
Control group
Active

Outcomes
Primary outcome [1] 327586 0
To compare the bioequivalence of (E)-4-methoxy-4-oxobut-2-enoic-acid (as summarised by Cmax and AUC) for the formulation. All plasma samples will be assayed for (E)-4-methoxy-4-oxobut-2-enoic-acid using a fully validated LC/MS/MS method. Validation will be conducted to comply with EU and FDA guidelines.
Timepoint [1] 327586 0
Prior to dosing and at 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 2.75, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 10, 11, 12 and 14 hours post dosing
Secondary outcome [1] 395783 0
Time to maximum peak concentration (Tmax) will be determined by plasma sample analysis. Tmax will be the time where the maximum concentration occurred in the sample points.
Timepoint [1] 395783 0
Prior to dosing and at 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 2.75, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 10, 11, 12 and 14 hours post dosing

Eligibility
Key inclusion criteria
Healthy males and non-pregnant female volunteers.
Aged between 18 and 55
Non-smoker
BMI between 18.5 and 32
Normal, healthy individuals as determined by medical history, physical examination, ECG, blood pressure and laboratory tests
Able to provide written informed consent
Minimum age
18 Years
Maximum age
55 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
Concomitant drug therapy of any kind
Any clinically significant medical conditions
Sensitive to the study drug
History of any conditions that might interfere with the absorption, distribution, metabolism or excretion of the drug
Females who are pregnant and/or breastfeeding
Smoker (anyone who has smoked in the last 6 months)
History of alcohol or drug abuse or dependency
Participation in a drug study within 60 days of the start of the study or donated blood within the 60 days preceding the study
Volunteers for whom the Clinical Investigator believer, for any reason, that participation would not be an acceptable risk

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
All formulations will be labelled as Formulation A and B. The identification of each treatment will only be known to the Managing Director and the Section Head - Trials and Regulatory Affairs.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Each participant will be given a 3 digit screening number and a 2 digit subject number. The screening number will be issued once the participant has given written consent to participate in the study and the two digit subject number (randomisation number) after acceptance into the study. Sequence generation will be by using a simple randomisation using a randomisation table created by computer software (i.e. computerised sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Crossover
Other design features
Phase
Phase 1
Type of endpoint/s
Bio-equivalence
Statistical methods / analysis

Recruitment
Recruitment status
Withdrawn
Reason for early stopping/withdrawal
Other reasons/comments
Other reasons
Sponsor withdrew the study.
Date of first participant enrolment
Anticipated
2/07/2021
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
39
Accrual to date
Final
Recruitment outside Australia
Country [1] 23714 0
New Zealand
State/province [1] 23714 0
Otago

Funding & Sponsors
Funding source category [1] 308644 0
Commercial sector/Industry
Name [1] 308644 0
Southern XP IP Pty Ltd
Country [1] 308644 0
Australia
Primary sponsor type
Commercial sector/Industry
Name
Zenith Technology Corporation Limited
Address
156 Frederick Street
North Dunedin
Dunedin 9016
Country
New Zealand
Secondary sponsor category [1] 309515 0
None
Name [1] 309515 0
Address [1] 309515 0
Country [1] 309515 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 308570 0
Northern A Health & Disability Ethics Committee
Ethics committee address [1] 308570 0
Ethics committee country [1] 308570 0
New Zealand
Date submitted for ethics approval [1] 308570 0
26/02/2021
Approval date [1] 308570 0
06/04/2021
Ethics approval number [1] 308570 0
21/NTA/37

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 111178 0
Dr Noelyn Hung
Address 111178 0
Zenith Technology Corporation Limited
156 Frederick Street (PO Box 1777)
Dunedin 9016
Country 111178 0
New Zealand
Phone 111178 0
+64 21 482 148
Fax 111178 0
+64 3 477 9605
Email 111178 0
noelyn.hung@otago.ac.nz
Contact person for public queries
Name 111179 0
Linda Folland
Address 111179 0
Zenith Technology Corporation Limited
156 Frederick Street (PO Box 1777)
Dunedin 9016
Country 111179 0
New Zealand
Phone 111179 0
+64 3 477 9669
Fax 111179 0
+64 3 477 9605
Email 111179 0
linda.folland@zenithtechnology.co.nz
Contact person for scientific queries
Name 111180 0
Tak Hung
Address 111180 0
Zenith Technology Corporation Limited
156 Frederick Street (PO Box 1777)
Dunedin 9016
Country 111180 0
New Zealand
Phone 111180 0
+64 3 477 9669
Fax 111180 0
+64 3 477 9605
Email 111180 0
tak.hung@zenithtechnology.co.nz

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
No/undecided IPD sharing reason/comment
All data will be compiled into a final report that is the property of the sponsor company. All participant data will be provided in summary format and result of the study only will be reported


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.